Condition
Attention Deficit and Disruptive Behavior Disorder
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Addon Placebo Following Optimized Methylphenidate
Related Conditions
Often studied with 4 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
1Total
Phase 2 (1)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Addon Placebo Following Optimized Methylphenidate1
- Addon Citalopram Following Optimized Methylphenidate1
Active Sponsors
- National Institute of Mental Health (NIMH)2
Top Investigators
National Institute of Mental Health (NIMH)
National Institute of Mental Health (NIMH)
Related Conditions
- Attention Deficit Disorder With Hyperactivity1
- Mental Disorder Diagnosed In Childhood1
- Attention Deficit Hyperactivity Disorder1
- Mood Disorder1